Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide. In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary outcome measures, with high statistical significance.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2020 All Rights Reserved